Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin’s impact on burden reduction
Substantial increases in comorbid CRM disease prevalence and associated healthcare resource strain in APAC are expected over the next decade. Guideline-directed SGLT2 inhibitor use, with empagliflozin as an example, may alleviate regional clinical and economic burden.
Authors
- J. Wee
- Lijoy Varghese (ORCID: https://orcid.org/0000-0002-6036-424X)
- Amrita Viswambaram (ORCID: https://orcid.org/0000-0002-6344-0252)
- Janis Lim (ORCID: https://orcid.org/0000-0001-5693-007X)
- Michael Kim (ORCID: https://orcid.org/0000-0001-5338-8393)
- Andrew Kean Seng Lim (ORCID: https://orcid.org/0000-0001-5290-7948)
- Emma New
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (China) (CN)
- Costello Medical Consulting (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1080/13696998.2025.2590401
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00